Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Mediterranean Journal of Hematology and Infectious Diseases 2026 Open access

Read full text
Authors: Nathalia Sena de Oliveira Silva, Gislaine Borba Oliveira Duarte, Samuel Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, K Pagnano
DOI: 10.4084/mjhid.2026.001
Cited by: 0

Abstract

Background: There is little data regarding hepatitis B (HBV) and C (HCV) prevalence in chronic myeloid leukemia (CML) patients at diagnosis and hepatitis reactivation during tyrosine kinase inhibitors (TKI) treatment.

Fields of Study & Subjects

Chronic Myeloid Leukemia Treatments Rheumatoid Arthritis Research and Therapies Myeloproliferative Neoplasms: Diagnosis and Treatment

Publication details

Journal / source
Mediterranean Journal of Hematology and Infectious Diseases
Volume
18
Issue
1
Pages
e2026001–e2026001
Publication date
1 January 2026
Language
EN